Inhibikase Therapeutics, Inc.
IKTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Inhibikase Therapeutics, Inc. (IKT) is listed under Biotechnology. Valued at $323.5M, IKT is a small-cap name in its sector. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
Market Cap
$323.5M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-5.42
EPS (TTM)
$-0.44
EPS (Fwd)
$-0.38
ROE
-40.2%
ROA
-22.6%
Cash
$170.4M
Total Debt
$0
Free CF
-$15.0M
52W Change
10.8%
Annual Financials
Cash vs Debt
Inhibikase Therapeutics, Inc. reports $170.4M in cash and $0 in total debt. Free cash flow is running at -$15.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -40.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IKT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.